drugset / Trial / NCT03740555
A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this First-in-Human study is to evaluate the safety , tolerability and pharmacokinetics after single ascending of HNC042 given to healthy subjects, compared to placebo. Also, the safety , tolerability and pharmacokinetics of multiple ascending of HNC042 given to healthy subjects daily for 7 days compared to placebo , will be evaluated.
Timeline
- Start
- 2018-11-09
- Primary completion
- 2019-07-19
- Completion
- 2019-07-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HNC042 | Unknown | 100 mg | Intravenous |
| Subject | HNC042 | Unknown | 300 mg | Intravenous |
| Subject | HNC042 | Unknown | 1200 mg | Intravenous |
Indications
No indication recorded.